BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

Private biotech companies held by funds formerly managed by Neil Woodford haven’t rid themselves of the debacle that led to the star British investor’s demise. According to a report in The Times that did not...
BioCentury | Nov 11, 2019
Emerging Company Profile

Mycovia tackling chronic infections with antifungal pipeline

Mycovia plans to bring a new generation of antifungals against CYP51 to market for difficult-to-treat indications, starting with chronic vaginal and nail infections. The company's lead product VT-1161 otesaconazole is in Phase III testing for...
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

Perhaps the greatest sign of robustness of the U.K. biotech sector is that it barely budged on the news this week of Neil Woodford’s demise. Woodford’s struggles came to an acrimonious and swift end as...
BC Extra | Oct 30, 2017
Company News

Management Tracks: Biohaven, Selecta

Neurology company Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) hired Clifford Bechtold as COO. He was development team leader for genetically defined diseases at Bristol-Myers Squibb Co. (NYSE:BMY). Immunology company Selecta Biosciences Inc. (NASDAQ:SELB) hired John...
BC Week In Review | Jan 13, 2017
Clinical News

VT-1161: Additional Ph IIb REVIVE data

Additional data from the double-blind, U.S. Phase IIb REVIVE trial in 215 patients with recurrent vulvovaginal candidiasis showed that 150 and 300 mg doses of oral VT-1161 once daily for 7 days and then once...
BC Week In Review | Jan 13, 2017
Clinical News

VT-1161: Additional Ph IIb RENOVATE data

Additional data from the double-blind, U.S. Phase IIb RENOVATE trial in 259 patients with distal lateral subungual onychomycosis of the large toenail showed that 300 and 600 mg doses of oral VT-1161 once daily for...
BC Week In Review | Oct 17, 2016
Clinical News

VT-1161 regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) designation to VT-1161 from Viamet to treat recurrent vulvovaginal candidiasis. VT-1161 is in a Phase IIb trial for the indication (see BioCentury, March 14). The product is an...
BC Week In Review | Sep 19, 2016
Clinical News

VT-1598 regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) designation to VT-1598 from Viamet to treat coccidioidomycosis (valley fever). VT-1598 is in preclinical testing. The compound is an oral inhibitor of fungal cytochrome P450 C-14 alpha demethylase...
BioCentury | Aug 22, 2016
Emerging Company Profile

Metal smithing

Forge Therapeutics Inc. is using a library of metal-binding pharmacophores that avoid known pharmacologic and safety liabilities of a common metal-binding motif to create inhibitors of metalloenzymes, starting with notoriously tough targets. Forge's lead program...
BC Extra | Jul 13, 2016
Company News

Management tracks

Oncology company Ipsen Group (Euronext:IPN) hired David Meek as CEO effective July 18, replacing Marc de Garidel. Meek was EVP and president of the oncology division at Baxalta Inc. , which Shire plc (LSE:SHP; NASDAQ:SHPG) acquired....
Items per page:
1 - 10 of 55
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

Private biotech companies held by funds formerly managed by Neil Woodford haven’t rid themselves of the debacle that led to the star British investor’s demise. According to a report in The Times that did not...
BioCentury | Nov 11, 2019
Emerging Company Profile

Mycovia tackling chronic infections with antifungal pipeline

Mycovia plans to bring a new generation of antifungals against CYP51 to market for difficult-to-treat indications, starting with chronic vaginal and nail infections. The company's lead product VT-1161 otesaconazole is in Phase III testing for...
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

Perhaps the greatest sign of robustness of the U.K. biotech sector is that it barely budged on the news this week of Neil Woodford’s demise. Woodford’s struggles came to an acrimonious and swift end as...
BC Extra | Oct 30, 2017
Company News

Management Tracks: Biohaven, Selecta

Neurology company Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) hired Clifford Bechtold as COO. He was development team leader for genetically defined diseases at Bristol-Myers Squibb Co. (NYSE:BMY). Immunology company Selecta Biosciences Inc. (NASDAQ:SELB) hired John...
BC Week In Review | Jan 13, 2017
Clinical News

VT-1161: Additional Ph IIb REVIVE data

Additional data from the double-blind, U.S. Phase IIb REVIVE trial in 215 patients with recurrent vulvovaginal candidiasis showed that 150 and 300 mg doses of oral VT-1161 once daily for 7 days and then once...
BC Week In Review | Jan 13, 2017
Clinical News

VT-1161: Additional Ph IIb RENOVATE data

Additional data from the double-blind, U.S. Phase IIb RENOVATE trial in 259 patients with distal lateral subungual onychomycosis of the large toenail showed that 300 and 600 mg doses of oral VT-1161 once daily for...
BC Week In Review | Oct 17, 2016
Clinical News

VT-1161 regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) designation to VT-1161 from Viamet to treat recurrent vulvovaginal candidiasis. VT-1161 is in a Phase IIb trial for the indication (see BioCentury, March 14). The product is an...
BC Week In Review | Sep 19, 2016
Clinical News

VT-1598 regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) designation to VT-1598 from Viamet to treat coccidioidomycosis (valley fever). VT-1598 is in preclinical testing. The compound is an oral inhibitor of fungal cytochrome P450 C-14 alpha demethylase...
BioCentury | Aug 22, 2016
Emerging Company Profile

Metal smithing

Forge Therapeutics Inc. is using a library of metal-binding pharmacophores that avoid known pharmacologic and safety liabilities of a common metal-binding motif to create inhibitors of metalloenzymes, starting with notoriously tough targets. Forge's lead program...
BC Extra | Jul 13, 2016
Company News

Management tracks

Oncology company Ipsen Group (Euronext:IPN) hired David Meek as CEO effective July 18, replacing Marc de Garidel. Meek was EVP and president of the oncology division at Baxalta Inc. , which Shire plc (LSE:SHP; NASDAQ:SHPG) acquired....
Items per page:
1 - 10 of 55